PO Box 9229
108 Biomedical Road
- Curriculum Vitae
- Download CV
- PhD, Michigan State University
Saumyendra N. Sarkar, Ashley E. Russell, Elizabeth B. Engler-Chiurazzi, Keyana N. Porter, and James W. Simpkins (2018). MicroRNAs and the Genetic Nexus of Brain Aging, Neuroinflammation, Neurodegeneration, and Brain Trauma. Aging and Disease 9(6). ISSN: 2152-5250
Shao-Hua Yang , Wenjun Li , Nathalie Sumien , Michael Forster , James W. Simpkins, Ran Liu, Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots, Progress in Neurobiology 157: 273-291, 2017.
E.B. Engler-Chiurazzi , C.M. Brown, J.M. Povroznik , J.W. Simpkins, Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury, Progress in Neurobiology 157: 188-211, 2017.
Elizabeth B. Engler-Chiurazzi, Douglas F. Covey, and James W. Simpkins, A Novel Mechanism of Non-feminizing Estrogens in Neuroprotection, Experimental Gerontology, 94:99-102.
Russell, AE, DN Doll, SN Sarkar and JW Simpkins, TNF-α and Beyond: Rapid Mitochondrial dysfunction mediates TNF-α-induced neurotoxicity, Journal of Clinical and Cellular Immunology, 2016, 7:6 DOI: 10.4172/2155-9899.1000467
S. Sarkar, S. Jun, S. Rellick, D.D. Quintana, J.Z. Cavendish, and J. W. Simpkins, Expression of MicroRNA-34a in Alzheimer’s Disease Brain Targets Genes Linked to Synaptic Plasticity, Energy Metabolism, and Resting State Network Activity, Brain Res. 1646: 139-151, 2016 PMID: 27235866
Randy Strong, Richard A. Miller, Adam Antebi, Clinton M. Astle, Molly Bogue, Martin Denzel, Elizabeth Fernandez, Kevin Flurkey, Karyn L. Hamilton, Dudley W. Lamming, Martin A. Javors, João Pedro de Magalhães, Joe M. McCord, Benjamin F. Miller, Michael Müller, James F. Nelson, Juliet Ndukum, G. Ed. Rainger, Arlan Richardson, David M. Sabatini, Adam Salmon, James W. Simpkins, Nancy L. Nadon, David E. Harrison, Longer lifespan in male mice treated with a non-feminizing steroid, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer, Aging Cell. 2016 Jun 16. doi: 10.1111/acel.12496. [Epub ahead of print] PMID: 27312235
Sarkar, S, S Jun, S, Rellick, S, and Simpkins, JW, Increased expression of miR-34a in late-onset Alzheimer’s disease (LOAD) brain mechanistically links synaptic plasticity and energy metabolism dysfunction, Brain Res. 1646: 139-151, 2016 PMID: 27235866
Doll DM, Rellick SL, Barr TL, Ren X, Simpkins JW. Rapid mitochondrial dysfunction mediates TNF-alpha induced neurotoxicity, J Neurochem. 2015;132(4):443-451. PMID:25492727
Doll DN, Hu H, Sun J, Lewis SE, Rellick SL, Simpkins JW, Ren X. Mitochondrial crisis in cerebrovascular endothelial cells opens the blood-brain barrier. Stroke 46: 1681-1689, 2015. PMID: 25922503
Sarkar S, Huang RQ, Logan SM, Dillon GH, Simpkins JW. Estrogens directly potentiate neuronal L-type Ca2 channels. Proc Natl Acad Sci USA. 2008;105(39):15148-15153. PMCID: PMC2575342.
Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova A, Perez E, Liu R, Simpkins JW. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA. 2003;100(20):11741—11746. PMCID: PMC208828.
Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan LJ, Ju X, Liu R, Qian H, Marvin MA, Goldberg MS, She H, Mao Z, Simpkins JW, Yang SH. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2001;286(18):16504-16515. PMCID: PMC3091255
Bodor N, Prokai L, Wu WM, Farag H, Joanalagadda S, Kawamura M, Simpkins JW. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science. 1992; 257(5077):1698-1700. PMID: 1529356
Bodor N, Simpkins JW. Redox delivery system for brain-specific, sustained release of dopamine. Science. 1983; 221(4605):65‑67. PMID: 6857264
About James W Simpkins
James W. Simpkins received his Ph.D. degree under the mentorship of the pioneering neuroendocrinologist, Joseph Meites at Michigan State University in 1977. He then jointed the University of Florida when he rose through the academic ranks to a full professorship in 1986. At the University of Florida, he was the founding director of the Center for the Neurobiology of Aging, served as Chair of two departments and was appointed the Frank Duckworth Professor of Drug Discovery in 1996. In 2000, he became the Professor and Chair of the Department of Pharmacology & Neuroscience and Founding Director of the Institute for Aging and Alzheimer’s Disease Research at the University of North Texas Health Science Center at Fort Worth. In 2012, he joined the faculty of the Department of Physiology and Pharmacology of West Virginia University and serves as the Founding Director of the Center for Basic and Translational Stroke Research. In 2012, he received the Harman Award for Life-time Achievement for Aging Research from the American Association of Aging. In 2015, he was named the Highland Chair of Stroke/Neurology at the WVU. The author of 420 full length publications, his research has focus on the discovery of novel compounds for the treatment of age-related brain disorders, with a particular focus on Alzheimer’s disease and stroke. His body of research has resulted in 22 issued US and foreign patents. He has mentored numerous PhD students, post-doctoral fellows and junior faculty to research and career success at the University of Florida, the University of North Texas Health Science Center and continued to do so at the West Virginia University.
Our lab studies the causes and potential treatment for Alzheimer’s disease (AD) and stroke in animal models and in human subjects. We are trying to understand the cause of brain damage from AD stroke and to develop treatments based on our understanding of causes. We use rats to induce stroke damage and a variety of techniques, including molecular biology, behavioral assessment and drug interventions to determine the causes and potential treatment for stroke damage. Our work also involves the use of transgenic mouse models, primarily for modeling AD. West Virginia has one of the highest incidences of stroke in the nation and currently therapies to limit stoke damage are limited. Our lab therefore is searching for novel treatments that can limit the damage and/or improve recovery from stroke.
Dana Foundation Blog: Dr. Simpkins on Stroke - http://danablog.org/2014/05/29/james-simpkins-on-stroke/
Center for Basic & Translational Stroke Research
- We assess the role of mitochondria in stroke propensity and stroke damage. These studies are aims at identifying the mechanism by which mitochondrial dysfunction contributes to stroke damage and the possibility of targeting drugs to these mitochondrial defects as a therapy for prevention/acute treatment of stroke.
- Assessment of vaious classes of drugs on neuroprotection in stroke and AD. We have a drug discovery program that attempts to discover novel compounds with efficacy in stroke and AD. One such class of compounds we have termed non-feminizing estrogens.
Structure and stroke protective effects of a non-feminizing estrogen (ZYC3)
- We assess the effects of beta amyloid on mitochondrial function to determine how this neurotoxic peptide causes loss of synapses and neurons in the brain.
Short-term treatment with beta amyloid (Abeta) causes a profound decline in mitochondrial function in promary neuronal cultures.